LeBron James, Nikola Jokić reportedly meet over $5bn upstart to rival NBA
The proposed league, spearheaded by Carter, would feature six men's and six women's teams that travel together to eight global cities in a touring format. Inspired by LIV Golf and Formula One, the league aims to offer players equity stakes, something NBA rules currently prohibit for active athletes.
Ražnatović, a powerful figure in European basketball, posted a photo of the meeting on Instagram over the weekend. The caption, tagged in Saint-Tropez, teased: 'The summer of 2025 is the perfect time to make big plans for the fall of 2026.' That photo fueled speculation about a potential team-up between James and Jokić, but sources confirmed to Front Office Sports the meeting was unrelated to the NBA.
This article includes content provided by Instagram. We ask for your permission before anything is loaded, as they may be using cookies and other technologies. To view this content, click 'Allow and continue'.
Carter began pitching the league earlier this year, with Bloomberg reporting in January that he is seeking to raise $5bn in funding. Backers already include the Singapore government, Saudi Arabia's Public Investment Fund, SC Holdings, UBS and investors such as Skype co-founder Geoff Prentice and former Facebook executive Grady Burnett.
Unlike the WNBA-adjacent Unrivaled league, which allows dual participation, Carter's venture is expected to require full-time commitments, effectively ruling out NBA participation unless league rules change.
The NBA, meanwhile, is pursuing its own expansion into Europe. Commissioner Adam Silver and deputy commissioner Mark Tatum met with UK prime minister Keir Starmer in London last week to discuss plans for a Europe-based NBA league in partnership with Fiba. As part of that effort, the NBA announced that the Orlando Magic and Memphis Grizzlies will play regular-season games in Berlin and London in January 2026.
EuroLeague officials have pushed back against the NBA's expansion talks. 'We said to them, like we said publicly, we don't believe that the new league is something that would help the market,' EuroLeague CEO Paulius Motiejūnas told the Athletic on Tuesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
29 minutes ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'
The Sun
37 minutes ago
- The Sun
Future of chain Claire's on UK high streets uncertain after US parent firm files for bankruptcy
FASHION accessories chain Claire's is facing an uncertain future on UK high streets, after its US parent firm filed for bankruptcy. It is the second time the ear-piercing favourite has declared itself bust, after previously filing for bankruptcy in 2018. 1 Its finances are now under pressure from weak consumer demand and supply chain uncertainty. The filings showed that the parent business reported liabilities of up to $10billion (£7billion) and owed between 25,000 and 50,000 creditors. Claire's operates 2,750 stores worldwide, including 280 in the UK. While British stores remain unaffected for now, the UK arm has lost £25million over the past three years and is at risk of collapsing into administration later this month. It has been working with advisers to explore a sale or restructuring. However, potential buyers, such as Hilco Capital, are understood to have walked away. Retail experts say Claire's is struggling to stay relevant. Julie Palmer, from Begbies Traynor, said: 'Claire's low-price offering is clearly not strong enough to win over its core customers — teens and young adults — as they now have access to a vast array of affordable and convenient products online through platforms like Amazon and Temu.' Claire's boss Chris Cramer said: 'We remain in active discussions with potential strategic and financial partners and are committed to completing our review of strategic alternatives.' Nostalgic 90's retailer files for bankruptcy after chain misses rent payments for June and July 'CORE BLIMEY! MINING giant Glenciore has decided to stick with its London stock listing, scrapping plans to shift to New York, in a win for the City. It has been listed on the FTSE since 2011, when it was valued at £37billion — at the time the exchange's largest float. However, the Swiss-based firm has announced plans to slash £753million in costs by 2026, including job cuts across its 150,000-strong workforce. METRO BANK ON THE UP METRO BANK has bounced back, posting a £43.1million pre-tax profit for the first half of 2025 — up from a £33.5million loss reported in the same period last year. The lender doubled new corporate and small business loans to £1billion, and cut 8 per cent from its costs by axing a third of its workforce and reducing branch hours. Boss Daniel Frumkin said: 'Our strong performance reflects the decisive actions we have taken.' Elsewhere, Sabadell shareholders have approved the £2.65billion sale of TSB to Santander.
The Guardian
an hour ago
- The Guardian
Premier League 2025-26 preview No 7: Chelsea
Guardian writers' predicted position: 4th (NB: this is not necessarily Michael Butler's prediction but the average of our writers' tips) Last season's position: 4th Securing Champions League qualification on the last day of the Premier League season and an unlikely Club World Cup triumph have transformed the club, their finances and ambitions for 2025-26. Chelsea stayed relatively under the radar for much of the Club World Cup – in part because of their relatively kind route to the later stages – but their commanding 3-0 victory against Paris Saint-Germain in the final means they are again regarded as a potentially dominant European force and perhaps even as contenders for the Premier League title. That is if Chelsea are ready – mentally, physically and tactically – for the new season. By the time Chelsea played the Club World Cup final on 13 July, nearly every other Premier League side had started their pre-season. Since then, while Liverpool, Arsenal and co have been hard at work, the players have had three weeks off and returned on Monday, with two friendly matches, two days apart, scheduled before their Premier League opener against Crystal Palace on 17 August. To say Chelsea are playing catch-up is a severe understatement. That said, this is probably the most exciting period for Chelsea since the Champions League triumph in 2021. With the exception of goalkeeper and possibly centre-back, Enzo Maresca has a claim to having two elite players in every position and he could yet add further depth with Xavi Simons and Alejandro Garnacho heavily linked. Departures will be needed to trim the fat and balance the books – Chelsea were given a €31m (£27m) fine last month by Uefa for breaking financial rules – but few would argue against them having the deepest squad in the league and one of Maresca's biggest challenges will be maintaining harmony and continuity, on and off the pitch. Last season, the Conference League was a useful chance to rest and rotate players. The Champions League will not be so accommodating. As recently as April, Maresca was at odds with the Chelsea fans and appeared to blame a negative environment at Stamford Bridge for a 2-2 home draw with Ipswich that left top-five hopes fading fast. But five wins from the final six league games secured fourth place, saving Chelsea's season and possibly Maresca's job. 'They were saying that we are too young, we are not good enough,' he said. 'Unfortunately for them, they have all been wrong. So in English, how do you say? Eff-off to all of them.' Chelsea's Club World Cup triumph – and the tactical masterclass by Maresca in the final to neutralise PSG's front three and create pockets of space for Cole Palmer – means he will get a very different reception at Stamford Bridge for Chelsea's league opener. Chelsea's much-maligned financial gymnastics of recent years – the eight-year contract amortisation (a loophole closed by Uefa), the sale of their hugely successful women's team (to their own parent company) and their rampant use of multiclub ownership and the loan system – have infuriated rivals and allowed them to assemble one of the deepest, youngest, most talented squads around. In the Todd Boehly era, Chelsea have spent more than £1.5bn and the club face an additional €60m fine from Uefa if they fail to comply with regulations over the next four years. A bigger stadium would help, but what Chelsea do with Stamford Bridge remains unclear; the 40,044-capacity ground is not easily developed given challenges ranging from the freehold to a nearby railway line. A move to Earl's Court has been mooted. Sign up to Football Daily Kick off your evenings with the Guardian's take on the world of football after newsletter promotion Estêvão was courted by PSG, Real Madrid, Barcelona and Bayern Munich and is widely regarded as the biggest talent to come out of Brazil since Vinícius Júnior. The 18-year-old's performances at the Club World Cup – including a brilliant strike for Palmeiras against Chelsea in the quarter-final – suggests that the summer arrival is already world class. Players swooned over the teenager at the final whistle in Philadelphia – 'I told Estêvão: 'We are excited for you to join' but he didn't understand a single word I said,' Palmer said after swapping shirts with the £52m signing. Capable off both wings or as a No 10, the slender Estêvão will want to impress the former Chelsea manager Carlo Ancelotti, now of Brazil, before the World Cup next summer. 'He potentially can be a top defender for this club,' Maresca said of Josh Acheampong after the defender's performances at the Club World Cup prompted whispers that several clubs in England and Europe were tracking the teenager. How the 19-year-old fits into Maresca's plans remains to be seen, but his versatility, 6ft 3in stature and composure enabled him to enjoy a breakthrough year with 13 first-team appearances. Naturally a right-back or a centre-back but capable of playing anywhere across the backline, Acheampong joined Chelsea as an under-eight and signed a new five-year contract in 2024. 'The clubs that were mentioned, they like Josh, but we also like Josh,' Maresca said. 'The best plan for Josh is to be with us.' Roméo Lavia. The 21-year-old's quality is not in question. Chelsea are a better side with Lavia, more fluid and press-resistant, and he was sensational in a 3-1 win against Liverpool in May when he completed 100% of his passes. Maresca even moved Moisés Caicedo to right-back to accommodate Lavia alongside Enzo Fernández at the back end of last season, but concerns remain over the Belgian's fitness. After a first year when he managed 32 minutes in 2023-24, another injury-hit campaign followed, starting 11 league games. Another year on the sidelines could spell trouble, particularly as Chelsea have Caicedo, Fernández, Dário Essugo, the impressive Andrey Santos and perhaps Reece James competing for two spots in defensive midfield in Maresca's preferred 4-2-3-1 formation.
